Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KENNETH W DAWES

Allopathic & Osteopathic Physicians Dermatology

NPI
1497758627
CMS profile
158180
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,395.83

137 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,395.83 137

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KENNETH W DAWES

NPI 1497758627 · CMS profile ID 158180

Allopathic & Osteopathic Physicians / Dermatology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

137 matching records · $2,395.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 137 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–137 of 137.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $19.6203/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594695 CMS
Lilly USA, LLC $13.3703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918118333 CMS
ABBVIE INC. $20.3803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838643 CMS
PFIZER INC. $5.6803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949570313 CMS
Amgen Inc. $8.3903/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939911961 CMS
Regeneron Healthcare Solutions, Inc. $13.0803/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927144935 CMS
LEO Pharma Inc. $19.8603/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936212007 CMS
ABBVIE INC. $17.7503/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838641 CMS
Janssen Research & Development, LLC $88.8403/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887129321 CMS
ABBVIE INC. $16.6903/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838639 CMS
Janssen Biotech, Inc. $3.3903/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896725 CMS
Janssen Biotech, Inc. $10.1902/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896749 CMS
ABBVIE INC. $22.2202/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838637 CMS
Novartis Pharmaceuticals Corporation $2.7302/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594691 CMS
ABBVIE INC. $17.3502/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838635 CMS
Janssen Biotech, Inc. $7.3902/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896731 CMS
Lilly USA, LLC $19.4202/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918158217 CMS
PFIZER INC. $6.2602/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949620447 CMS
Novartis Pharmaceuticals Corporation $12.7902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594685 CMS
UCB, Inc. $14.5102/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907992639 CMS
Novartis Pharmaceuticals Corporation $119.3702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594677 CMS
Regeneron Healthcare Solutions, Inc. $13.3302/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927144931 CMS
PFIZER INC. $6.0802/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949189365 CMS
ABBVIE INC. $7.1402/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838633 CMS
Novartis Pharmaceuticals Corporation $3.8502/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594689 CMS
Janssen Biotech, Inc. $3.0702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896719 CMS
Janssen Biotech, Inc. $7.9401/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896785 CMS
Janssen Biotech, Inc. $15.0301/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896777 CMS
ABBVIE INC. $27.8401/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838631 CMS
ABBVIE INC. $27.0201/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838629 CMS
Amgen Inc. $8.2601/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939911957 CMS
Novartis Pharmaceuticals Corporation $1.3101/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594683 CMS
Novartis Pharmaceuticals Corporation $1.5101/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594687 CMS
Novartis Pharmaceuticals Corporation $1.5501/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893594681 CMS
ABBVIE INC. $18.5901/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890838627 CMS
Janssen Biotech, Inc. $3.5001/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896715 CMS
Janssen Biotech, Inc. $11.6001/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885896773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,373.22 153
PY2020 $7,586.14 78
PY2021 $2,188.99 106
PY2022 $2,395.83 137
PY2023 $2,534.22 160
PY2024 $9,334.34 103
PY2025 $18,418.68 143

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $83,504.70 17
PY2025 Principal investigator $220,987.57 249
PY2024 Principal investigator $470,955.36 225
PY2023 Recipient $629.00 1
PY2023 Principal investigator $411,376.39 220
PY2022 Principal investigator $377,634.04 111
PY2021 Principal investigator $161,324.51 36
PY2020 Principal investigator $233,008.04 29
PY2019 Recipient $3,500.00 1
PY2019 Principal investigator $288,143.32 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

266 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $410.04 12/29/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431304
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,326.42 12/19/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262860
Principal investigator 1 Incyte Corporation $951.30 12/11/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522558
Principal investigator 1 Incyte Corporation $58.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522562
Principal investigator 1 Incyte Corporation $220.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522569
Principal investigator 1 Incyte Corporation $883.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522573
Principal investigator 1 Incyte Corporation $546.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522598
Principal investigator 1 Incyte Corporation $140.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522605
Principal investigator 1 Incyte Corporation $732.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522611
Principal investigator 1 Incyte Corporation $132.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522617
Principal investigator 1 Incyte Corporation $152.00 12/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522626
Principal investigator 1 Incyte Corporation $7,009.30 12/08/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522601
Principal investigator 1 Incyte Corporation $606.10 12/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522554
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521811
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521816
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522579
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522594
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522614
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522630
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522633
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522641
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522645
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522649
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522653
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,008.30 12/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262858
Principal investigator 1 Incyte Corporation $4,500.00 11/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522546
Principal investigator 1 Incyte Corporation $1,500.00 11/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522550
Principal investigator 1 Incyte Corporation $1,915.20 11/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522565
Principal investigator 1 Incyte Corporation $1,000.00 10/23/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522590
Principal investigator 1 Incyte Corporation $1,500.00 10/23/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522637
Principal investigator 1 Incyte Corporation $2,345.00 10/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522582
Principal investigator 1 Incyte Corporation $95.80 10/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522622
Principal investigator 1 SANOFI US SERVICES INC. $13,300.00 10/20/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226113726
Principal investigator 1 Incyte Corporation $1,125.90 10/16/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522534
Principal investigator 1 Incyte Corporation $951.30 10/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522538
Principal investigator 1 Incyte Corporation $1,125.90 10/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522542
Principal investigator 1 Incyte Corporation $2,110.50 10/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522586
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,302.30 09/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431302
Principal investigator 1 Incyte Corporation $1,376.10 09/10/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522525
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 09/05/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262854
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/05/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262856
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,729.00 09/03/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262852
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521734
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521738
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521742
Principal investigator 1 Incyte Corporation $2.12 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521746
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521750
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521754
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521757
Principal investigator 1 Incyte Corporation $12.72 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521766
Principal investigator 1 Incyte Corporation $59.13 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521771
Principal investigator 1 Incyte Corporation $11.45 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521775
Principal investigator 1 Incyte Corporation $135.40 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521782
Principal investigator 1 Incyte Corporation $16.18 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521786
Principal investigator 1 Incyte Corporation $62.27 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521790
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521799
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521803
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,792.08 08/22/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262850
Principal investigator 1 Incyte Corporation $1,156.50 08/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522440
Principal investigator 1 Incyte Corporation $1,593.00 08/20/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522444
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,637.55 08/20/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262848
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521762
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521779
Principal investigator 1 Incyte Corporation $57.25 08/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521795
Principal investigator 1 Incyte Corporation $48.54 08/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521807
Principal investigator 1 Incyte Corporation $1,376.10 08/04/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522453
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $546.72 07/28/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431298
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,246.20 07/28/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431300
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,657.20 07/23/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262846
Principal investigator 1 Incyte Corporation $2,251.80 07/22/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240522436
Principal investigator 1 Incyte Corporation $1,583.60 07/18/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522460
Principal investigator 1 Incyte Corporation $2,345.00 07/18/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522464
Principal investigator 1 Incyte Corporation $1,462.00 07/18/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522480
Principal investigator 1 Incyte Corporation $1,462.00 07/18/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522484
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,085.40 07/18/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431296
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,985.00 07/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190300125
Principal investigator 1 Incyte Corporation $1,376.10 07/09/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522449
Principal investigator 1 Incyte Corporation $8.22 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522456
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522469
Principal investigator 1 Incyte Corporation $7.29 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522473
Principal investigator 1 Incyte Corporation $34.35 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522476
Principal investigator 1 Incyte Corporation $16.18 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522487
Principal investigator 1 Incyte Corporation $4.24 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522491
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522496
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522501
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522505
Principal investigator 1 Incyte Corporation $8.22 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522509
Principal investigator 1 Incyte Corporation $8.22 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522512
Principal investigator 1 Incyte Corporation $8.22 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522516
Principal investigator 1 Incyte Corporation $24.68 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522520
Principal investigator 1 Incyte Corporation $0.31 07/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522529
Principal investigator 1 Incyte Corporation $2,345.00 06/25/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522369
Principal investigator 1 Incyte Corporation $935.10 06/25/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522374
Principal investigator 1 Incyte Corporation $1,462.00 06/25/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522422
Principal investigator 1 SANOFI PASTEUR INC. $10,132.75 06/25/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Gro LLC
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226103889
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,302.30 06/18/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431294
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,287.60 06/11/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262844
Principal investigator 1 Incyte Corporation $49.36 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522358
Principal investigator 1 Incyte Corporation $91.60 06/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522396
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 05/28/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262842
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,085.40 05/27/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431292
Principal investigator 1 Organon Llc $2,045.10 05/26/2025 Non-covered Recipient Entity
RM Medical Research, Inc.
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042008
Principal investigator 1 Eli Lilly and Company $9,183.00 05/21/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187879715
Principal investigator 1 Incyte Corporation $2,215.00 05/21/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522338
Principal investigator 1 Incyte Corporation $2,215.00 05/21/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522345
Principal investigator 1 Incyte Corporation $872.80 05/21/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522353
Principal investigator 1 Incyte Corporation $1,376.10 05/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522350
Recipient Takeda Pharmaceuticals U.S.A., Inc. $6,939.09 05/07/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262840
Principal investigator 1 Incyte Corporation $2,215.00 05/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522362
Principal investigator 1 Incyte Corporation $1,094.30 05/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522366
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,690.00 04/17/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431290
Principal investigator 1 Eli Lilly and Company $1,800.00 04/07/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187880755
Principal investigator 1 Incyte Corporation $1,462.00 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522343
Principal investigator 1 Incyte Corporation $28.84 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522378
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522382
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522384
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522387
Principal investigator 1 Incyte Corporation $26.50 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522392
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522401
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522405
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522409
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522413
Principal investigator 1 Incyte Corporation $1,169.60 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522418
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522427
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522432
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11,192.38 03/26/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262838
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,085.40 03/24/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,342.00 03/19/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184174554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 03/19/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184174556
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,767.70 03/14/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262836
Principal investigator 1 Incyte Corporation $1,504.80 03/12/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521876
Principal investigator 1 Incyte Corporation $2,336.00 03/05/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521873
Principal investigator 1 Incyte Corporation $1,023.40 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521880
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522088
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522091
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522097
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522101
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522122
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522131
Principal investigator 1 Incyte Corporation $7.29 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522135
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522139
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522143
Principal investigator 1 Incyte Corporation $0.31 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522145
Principal investigator 1 Incyte Corporation $137.40 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522149
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522173
Principal investigator 1 Incyte Corporation $24.68 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522194
Principal investigator 1 Incyte Corporation $8.22 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522288
Principal investigator 1 Incyte Corporation $1,462.00 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522331
Principal investigator 1 Incyte Corporation $1,462.00 03/03/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522334
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,473.10 03/03/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431286
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,425.00 02/21/2025 Non-covered Recipient Entity
Dawes Fretzin Dermatology Group, Llc
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis No dispute reported 06/30/2026 1235997756
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,290.28 02/21/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262834
Principal investigator 1 Incyte Corporation $1,344.80 02/19/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521842
Principal investigator 1 Incyte Corporation $1,618.00 02/19/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521858
Principal investigator 1 Eli Lilly and Company $11,679.85 02/11/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187879791
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,860.80 02/07/2025 Non-covered Recipient Entity
Dawes Fretzin Clinical Research Group, LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246431284
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521946
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521968
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521974
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521977
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521981
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521985
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521989
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521993
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240521997
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522000
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522002
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522006
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522009
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522015
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522020
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522024
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522030
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522034
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522039
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522043
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522046
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522050
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522054
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522058
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522062
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522066
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522069
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522074
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522078
Principal investigator 1 Incyte Corporation $6.52 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522081
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522085
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522106
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522110
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522114
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522118
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522127
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522154
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522163
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522169
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522190
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522204
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522211
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522222
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522226
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522229
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522233
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522237
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522241
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522244
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522249
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522253
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522257
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522322
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240522326
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9,769.51 02/05/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262832
Principal investigator 1 Organon Llc $2,623.20 02/03/2025 Non-covered Recipient Entity
RM Medical Research, Inc.
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041982
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,772.07 02/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190308122
Principal investigator 1 Incyte Corporation $1,572.00 01/27/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521846
Principal investigator 1 Incyte Corporation $1,572.00 01/27/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521850
Principal investigator 1 Incyte Corporation $1,679.10 01/27/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521861
Principal investigator 1 Incyte Corporation $2,111.40 01/17/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521828
Principal investigator 1 Incyte Corporation $1,462.00 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521819
Principal investigator 1 Incyte Corporation $1,572.00 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521823
Principal investigator 1 Incyte Corporation $487.50 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521832
Principal investigator 1 Incyte Corporation $1,572.00 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521838
Principal investigator 1 Incyte Corporation $2,215.00 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521854
Principal investigator 1 Incyte Corporation $1,462.00 01/15/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522186
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,747.93 01/08/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262830
Principal investigator 1 Organon Llc $3,300.00 01/07/2025 Non-covered Recipient Entity
RM Medical Research, Inc.
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041974
Recipient Takeda Pharmaceuticals U.S.A., Inc. $7,559.66 01/03/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262828
Principal investigator 1 Incyte Corporation $164.30 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521865
Principal investigator 1 Incyte Corporation $185.50 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521868
Principal investigator 1 Incyte Corporation $121.90 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521884
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521888
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521893
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521897
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521903
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521907
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521911
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521915
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521919
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521925
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521930
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521934
Principal investigator 1 Incyte Corporation $24.68 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521938
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521942
Principal investigator 1 Incyte Corporation $6.18 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521950
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521956
Principal investigator 1 Incyte Corporation $0.62 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521960
Principal investigator 1 Incyte Corporation $7.29 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240521964
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522158
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522177
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522183
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522199
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522207
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522218
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522261
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522265
Principal investigator 1 Incyte Corporation $22.90 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522270
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522277
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522281
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522285
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522293
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522297
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522301
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522304
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522308
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522312
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH GROUP LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240522318
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,249.36 01/01/2025 Non-covered Recipient Entity
DAWES FRETZIN CLINICAL RESEARCH
A randomized subject and investigator blinded placebo controlled and multi center platform study to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1190308120